Jean-François Millau
CEO, co-founder
Kevin Neil
CTO, co-founder
Sébastien Rodrigue
CSO, co-founder
leverages synthetic biology to build a category-defining platform based on engineered phages capable of multitasking immunotherapies to break cancer resistances. This first-in-class modality triggers full-blown antitumor immune responses providing unparalleled clearance efficacy.
Advice for entrepreneurs
“ Stay humble and know how to surround yourself well! ”
- Jean-François Millau